Document:

Exhibit 10.15

 

REDACTED

  Certain identified information, indicated by [*****],
has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly
disclosed.

 

RESTATED AMENDMENT

 

TO DEVELOPMENT AND OPTION AGREEMENT

 

THIS RESTATED AMENDMENT TO DEVELOPMENT AND
OPTION AGREEMENT (this “Amendment”), dated as of September 28, 2018 (the “Amendment Restatement Date”),
is made by and between CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tubingen, Germany
(“CureVac”), and Arcturus Therapeutics Inc., a Delaware corporation with offices at 10628 Science Center Drive
#200, San Diego, CA 92121, USA (“Arcturus”). Each of CureVac and Arcturus may be referred to herein as a “Party”
or together as the “Parties”.

 

WHEREAS, the Parties are parties to that
certain Development and Option Agreement, dated as of January 1, 2018 (the “Development and Option Agreement”);

 

WHEREAS, an amendment to the Development
and Option Agreement was executed by the Parties on May 8, 2018 (“Original Amendment”); and

 

WHEREAS, CureVac and Arcturus desire to
amend and restate the Original Amendment in its entirety, effective as of the Amendment Restatement Date.

 

NOW, THEREFORE, in consideration of the
foregoing and the promises and mutual agreements contained in this Amendment, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the Parties agree as follows:

 

SECTION 1. Amendment and Restatement
of Original Amendment.

 

The Original Amendment is hereby amended
and restated in its entirety as of the Amendment Restatement Date, and all provisions of, and rights granted and covenants made
in the Original Amendment, if and to the extent not restated herein, are hereby waived, released and superseded in their entirety
and shall have no further force or effect.

 

SECTION 2. Irrevocable Offer.

 

(a)       The
heading of Article 5 of the Development and Option Agreement is hereby amended and restated in its entirety as follows: “Irrevocable
Offer to Licenses” and the Table of Contents is updated accordingly. The heading of Section 5.1 of the Development and Option
Agreement is amended and restated in its entirety as follows: “Irrevocable Offer.”

 

(b)       Section
5.1(a) of the Development and Option Agreement is hereby amended and restated in its entirety as follows:

 

“(a)     Arcturus hereby makes a final,
binding irrevocable offer (the “Irrevocable Offer”) to CureVac to enter into, on the terms of, and subject to
the conditions set forth in, the Exclusive License Agreement or, if the Reserved Target is only available on a non-exclusive basis,
the Non-Exclusive License Agreement, on a Reserved Target-by-Target basis, a maximum of [*****] under the Arcturus LMD Technology
with respect to the development, manufacture and commercialization of Licensed Products containing mRNA Constructs intended to
express such Reserved Target in the form of the License Agreement. Upon the execution of this Amendment, the Irrevocable Offer
shall remain valid and legally binding on Arcturus and in effect, and the Irrevocable Offer from Arcturus shall be irrevocable
and open for acceptance from CureVac for the period commencing on the Effective Date and ending on the expiration of the Term (the
 “Offer Period”).”

 

(c)       Section
5.1(b) of the Development and Option Agreement is hereby amended and restated in its entirety as follows:

 

     

     

    

 

“(b)     If, prior to the expiration
of the Offer Period, CureVac delivers written notice to Arcturus of its intention to enter into a license for a Reserved Target,
which such notice shall set forth the particular Reserved Target which is intended to be expressed by the Licensed Products (each
such notice, an “Acceptance Notice”), then upon delivery thereof, for the Reserved Target set forth in such
Acceptance Notice, the licenses and all other rights under the applicable License Agreement shall immediately be in effect without
the requirement of either Party to execute any further documentation and there shall exist a legal, valid and binding obligation
of Arcturus, enforceable against Arcturus in accordance with the terms of the Exclusive License Agreement or, if the Reserved Target
set forth in such Acceptance Notice is only available on a non-exclusive basis, the Non-Exclusive License Agreement. A separate
Acceptance Notice and Acceptance Fee will be required for each License Agreement with respect to which CureVac accepts the Irrevocable
Offer pursuant to this Section 5.1, and CureVac will pay to Arcturus the Acceptance Fee for each such License Agreement as set
forth in Section 5.3. In the event that CureVac terminations a license(s) during the Term, the Target(s) subject to the license(s)
will be removed from the Reserved Target List and the number of License Agreements for which the Irrevocable Offer exists shall
be reduced by one (1) (i.e. the delivery of an Acceptance Notice reduces the total number of License Agreements for which CureVac
may accept the Irrevocable Offer by one regardless of whether CureVac elects to continue such License Agreement in effect).”

 

(d)       Section
5.1(c) of the Development and Option Agreement is hereby amended and restated in its entirety as follows:

 

“(c)     In the event that CureVac
terminates a License Agreement during the Term, the Targets subject to such license(s) will no longer be available as a Target
pursuant to this Agreement.”

 

(e)       Section
5.2 of the Development and Option Agreement is hereby amended and restated in its entirety as follows:

 

“5.2     CureVac’s
Acceptance of Irrevocable Offer. As soon as practicable following CureVac’s delivery of each Acceptance Notice to Arcturus,
CureVac and Arcturus will prepare the appendices to the corresponding License Agreement. The License Agreement shall nevertheless
enter into force (including payment obligations of CureVac in accordance with the terms of the License Agreement) upon delivery
of the Acceptance Notice by CureVac.”

 

(f)       Section
5.3 of the Development and Option Agreement is hereby amended and restated in its entirety as follows:

 

“5.3     Acceptance
Fee. If CureVac delivers an Acceptance Notice for a Rare Disease Target pursuant to Section 5.1, CureVac shall pay an
Acceptance Fee of [*****] and if CureVac delivers an Acceptance Notice for a Non-Rare Disease Target pursuant to Section 5.1,
CureVac shall pay an Acceptance Fee of [*****], hereinafter both the “Acceptance
Fee”. On the [*****] day that it delivers an Acceptance Notice, CureVac shall pay the applicable Acceptance Fee by
wire transfer in immediately available funds to the bank account of Arcturus set forth on Schedule 3 (or such other
bank account notified in writing to CureVac prior to such date).”

 

(g)       Section
5.4 of the Development and Option Agreement is hereby amended and restated in its entirety as follows:

 

“5.4     Co-Development Agreement.
For clarification, the selection of any program under the Co-Development Agreement shall not constitute the delivery of an Acceptance
Notice in accordance with this Section 5, and, accordingly, no Acceptance Fee will be payable and any paid Acceptance Fee shall
be credited against any other payments by CureVac applied first to any outstanding payment obligations to Arcturus, and to the
extent any remaining amounts remain creditable, then to the next due future payment obligations.”

 

(g)       Definitions.
Each of the following Sections of the Development and Option Agreement are hereby amended and restated in their entirety as “Intentionally
Omitted.” : Section 1.35, Section 1.62, Section 1.64, Section 1.65, Section 1.66 and Section 1.67 The following Sections
are inserted immediately following Section 1.94 of the Development and Option Agreement:

    2

     

    

 

“1.95  “Irrevocable
Offer” has the meaning set forth in Section 5.1(a).

 

1.96    “Acceptance
Notice” has the meaning set forth in Section 5.1(b).

 

1.97   “Acceptance
Fee” has the meaning set forth in Section 5.3.”

 

(h)       Additional
Modifications.

 

(i) In Section 3.1(f) of the Development
and Option Agreement, the occurrence of “exercise of an Option and entry into a License Agreement” in the first sentence
is hereby replaced with “delivery of an Acceptance Notice and the entering into force of a License Agreement”.

 

(ii) In Section 3.3(c) of the
Development and Option Agreement, the occurrence of “whether to exercise an Option” in the third sentence is hereby
replaced with “whether to delivery an Acceptance Notice”.

 

(iii) In Section 4.2(c)(iii) of
the Development and Option Agreement, the occurrence of “option” in the second sentence is hereby replaced with “right”.

 

(iv) In Section 4.2(d)(ii) of
the Development and Option Agreement, the occurrence of “shall be reduced by each exercise of an Option” in the first
sentence is hereby replaced with “shall be reduced by each delivery of an Acceptance Notice” and the occurrence of
 “applying from and after the date of exercise of an Option.” in the first sentence is hereby replaced with “applying
from and after the date of an Acceptance Notice.”.

 

(v) In Section 6.4(c)(ii) of the
Development and Option Agreement, the occurrence of “an Option Notice” in the first sentence is hereby replaced with
 “an Acceptance Notice”.

 

(vi) In Section 6.4(c)(iii) of
the Development and Option Agreement, the occurrence of “to the Options” in the first sentence is hereby replaced with
 “pursuant to the Irrevocable Offer”.

 

(vii) In Section 9.2(a)(iv) of
the Development and Option Agreement, the occurrence of “the Option Exercise Fee” is hereby replaced with “the
Acceptance Fee”.

 

(viii)vIn Section 9.2(a) of the
Development and Option Agreement, in the sentence immediately following subsection (iv), the occurrence of “or the Options”
is hereby replaced with “or the Irrevocable Offers”.

 

SECTION 3. License Agreements.

 

(a)       “Non-Exclusive
License Agreement” means the terms of the Non-Exclusive License Agreement agreed by the Parties, incorporated by reference
into the Development and Option Agreement and set forth on Schedule 1-A to this Amendment.

 

(b)       “Exclusive
License Agreement” means the terms of the License Agreement agreed by the Parties, incorporated by reference into the
Development and Option Agreement and set forth on Schedule 1-B to this Amendment.

 

SECTION 4. Termination of Security Interest.
CureVac acknowledges and agrees that the security interests in, and Liens (as defined in the Original Amendment) on, the Collateral
(as defined in the Original Amendment) in favor of CureVac are released and terminated. CureVac shall promptly prepare and file
a UCC termination statement in order to evidence the termination of the Liens and security interests granted pursuant to the Original
Amendment.

 

    3

     

    

 

SECTION 5. Additional Expenses. In
consideration for the rights granted pursuant to Section 2 of this Amendment, CureVac agrees to perform the Work under the
Work Plan as part of which CureVac will fund [*****] scientists per year at Arcturus for a period of [*****]
months at the FTE Costs.

 

SECTION 6. Targets. In consideration
for the termination of the security interests granted to CureVac in the Original Amendment, Arcturus agrees that CureVac will have

 

(a)       the
right to select up to [*****] Targets at any one time to be placed on the Reserved Target List as exclusive Reserved Targets
according to Section 4.2(d)(ii) the Development and Option Agreement and

 

(b)       a
total of [*****] options, on a Reserved Target-by-Reserved Target basis, to enter into a maximum of [*****] licenses under
the Arcturus LMD Technology with respect to the development, manufacture and commercialization of Licensed Products containing
mRNA Constructs in accordance with Section 5.1 of the Development and Option Agreement.

 

SECTION 7. Representations and Warranties.
Each Party represents and warrants to the other as of the Amendment Restatement Date that (a) it is a corporation duly organized,
validly existing, and in good standing under the Laws of the jurisdiction in which it is incorporated, (b) it has the legal right
and power to enter into this Amendment, to extend the rights and licenses granted or to be granted to the other in the Development
and Option Agreement, and to fully perform its obligations hereunder, (c) it has taken all necessary corporate action on its part
required to authorize the execution and delivery of this Amendment and the performance of its obligations under the Development
and Option Agreement (d) this Amendment has been duly executed and delivered on behalf of such Party, and constitutes a legal,
valid, and binding obligation of such Party that is enforceable against it in accordance with its terms, and (e) the execution,
delivery and performance by a Party of this Amendment and the consummation of the transactions contemplated hereby will not result
in any violation of, conflict with, result in a breach of or constitute a default under any understanding, contract or agreement
to which such Party is a party or by which it is bound.

 

SECTION 8. Ratification of Agreement.
Except as expressly provided in this Amendment, all of the terms, covenants, and other provisions of the Development and Option
Agreement are hereby ratified and confirmed and shall continue to be in full force and effect in accordance with their respective
terms. From and after the date hereof, all references to the Development and Option Agreement shall refer to the Development and
Option Agreement as amended by this Amendment. Capitalized terms used but not defined in this Amendment shall have the meanings
assigned to them in the Development and Option Agreement.

 

SECTION 9. Governing Law. This Amendment
shall be governed by and construed in accordance with the Laws of the State of New York, USA, without respect to its conflict of
Laws rules. In the event of a dispute arising out of or relating to this Amendment, the provisions of Section 10.1 of the Development
and Option Agreement shall govern the resolution of such dispute.

 

SECTION 10. Counterparts. This Amendment
may be executed and in one or more counterparts, each of which will be deemed an original, and all of which together will be deemed
to be one and the same instrument. Facsimile or PDF execution and delivery of this Amendment by either Party will constitute a
legal, valid and binding execution and delivery of this Amendment by such Party.

 

[signature page follows]

    4

     

    

 

IN
WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their respective duly authorized officers
as of the date hereof.

 

	 	 	CUREVAC AG
	 	 	 
		 	By:	/s/ Daniel L. Menichella
	 	 	 	Name:	Daniel L. Menichella
	 	 	 	Title:	Chief Executive Officer
	 	 	 
	 	 	ARCTURUS THERAPEUTICS INC.
	 	 	 
		 	By:	/s/ Joseph E. Payne
	 	 	 	Name:	Joseph E. Payne
	 	 	 	Title:	Chief Executive Officer

 

    	 	5	 

     

    

 

Schedule 1-A

 

Non-Exclusive License Agreement

 

 

See Original Amendment.

 

    	 	6	 

     

    

 

Schedule 1-B

 

Exclusive License Agreement

 

 

 

See Original Amendment.

  

    7

     

    

 

Schedule 3

 

[*****]

  

    8Exhibit 10.16

 

REDACTED

Certain identified
information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would
likely cause competitive harm if publicly disclosed.

 

THIS THIRD AMENDMENT
(this “Third Amendment”) to the Development and Option Agreement dated January 1, 2018 (the “Original
Agreement”), is entered into by and between CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse
15, 72076 Tubingen, Germany (“CureVac”), and Arcturus Therapeutics Inc., a Delaware corporation with offices
at 10628 Science Center Drive #200, San Diego, CA 92121, USA (“Arcturus”; each of CureVac and Arcturus individually
a “Party” and together the “Parties”) as of July 26, 2019 (the “Third Amendment
Date”).

 

RECITALS

 

WHEREAS, the Parties
have previously amended the Original Agreement by (i) a first amendment dated May 3, 2018 (the “First Amendment”)
and (ii) a second amendment amending and restating the First Amendment in its entirety dated September 28, 2018 (the “Second
Amendment”; the Original Agreement, as amended to the date hereof by the First Amendment and the Second Amendment, being
referred to as the “Development and Option Agreement”).

 

WHEREAS, the Parties
desire to amend the Development and Option Agreement effective as of the Third Amendment Date.

 

NOW, THEREFORE, in
consideration of the foregoing and the promises and mutual agreements contained in this Third Amendment, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the Parties
agree as follows:

 

1.       DELETION
OF SECTION 5 AND SECTION 6 OF THE SECOND AMENDMENT

 

		(a)	Section 5 of the Second Amendment is hereby deleted in its entirety and shall have no further force
and effect. Section 3.2(a) of the Original Agreement shall be restored as to its substance from and after the Third Amendment Date,
and, for clarification purposes, is hereby amended and restated as follows:

 

“(a)Generally.
Arcturus will perform the Work under the Work Plan, and as part of the Program CureVac will fund up to three (3) scientists
per year at Arcturus to perform the Work as defined and in accordance with the Work Plan for a period of up to twenty-four (24)
months beginning at the Third Amendment Date at the FTE Costs. The Parties may agree to extend the performance of Work by Arcturus
for an additional year.”

 

		(b)	Section 6 of the Second
Amendment is hereby deleted in its entirety and shall have no further force and effect. Section 4.2(d)(ii) (Maximum Number Reserved
Targets) and Section 5.1(a) (Maximum Options) of the Original Agreement are hereby restored with the effect that the maximum number
of Reserved Targets and the total number of Options to enter into a maximum number of licenses under the Arcturus LMD Technology
are reduced from [*****].

 

2.       AMENDMENT
OF ARTICLE 9 OF THE DEVELOPMENT AND OPTION AGREEMENT

 

		(a)	Section 9.1(a) and Section 9.1 (b) of the Development and Option Agreement are hereby amended and
restated in their entirety as follows:

 

“(a)      This
Agreement will commence as of the Effective Date and, unless sooner terminated or extended in accordance with the terms hereof
or by mutual written consent, will continue for a period of four (4) years from the Third Amendment Date, (the “Initial
Term”, as may be extended pursuant to Section 9.1(b), the “Term”).

 

(b)       At
any time during the Initial Term, CureVac shall have the option to extend the Initial Term for eighteen (18) months, by
providing written notice to Arcturus, subject to payment by CureVac to Arcturus of a non-refundable extension fee of one million US dollars (U.S. $1,000,000),
payable within fifteen (15) Business Days after notice of the exercise of such option. If the $1,000,000 payment is not made
within such fifteen (15) Business Day period the Term will be the Initial Term without extension.”

 

     

     

    

 

		(b)	Section 9.1(c) of the Development and Option Agreement is hereby amended and restated in its entirety
as “Intentionally Omitted”.

 

		(c)	Section 9.2, first paragraph of the Development and Option Agreement is hereby amended and restated
in its entirety as follows:

 

“(9.2)       Termination
by CureVac.

 

(a)       Breach,
Change of Control. CureVac will have the right to terminate this Agreement in full or on a Program-by-Program
basis upon delivery of written notice to Arcturus in the event of

 

(i) any material breach by Arcturus

 

(A) of any terms and conditions
of this Agreement, provided that such breach has not been cured within sixty (60) days after written notice thereof is given by
CureVac to Arcturus specifying in reasonable detail the nature of the alleged breach; or

 

(B) in particular the failure
of the Trusted Arcturus Employee to send the Target Response Notice within the period provided for in Section 4.2(c)(i), provided
that such failure has not been cured neither within a first cure period of five (5) Business Days after written notice thereof
is given by CureVac to Arcturus nor within a second cure period of five (5) Business Days after written notice of the lapse of
the first cure period is given by CureVac to Arcturus, or

 

(ii) a Change of Control of Arcturus.”

 

3.       AMENDMENT
OF ARTICLE 4 OF THE OPTION AND DEVELOPMENT AGREEMENT

 

Article 4 of the Development
and Option Agreement is hereby amended and restated in its entirety as follows:

 

“ARTICLE 4

Reserved Targets

 

4.1       Generally.
CureVac will select the Targets that will be the subject of the Works to be performed as part of a Program from the Reserved Target
List. CureVac shall have the right, but not the obligation, to reserve Targets (or replace a Reserved Target with a new Target)
in accordance with this Article 4.

 

		4.2	Restricted Target List.

 

(a)       Pre-existing
Restrictions. Arcturus shall ensure that the Trusted Arcturus Employee has access to an updated list of Targets
that are subject to Pre-Existing Restrictions at any time (the “Restricted Target List”). The Restricted Target
List will identify for each Target listed in the Restricted Target List whether the Target is subject to Third Party rights or
is under development at Arcturus. If the Target is subject to Third Party rights, the Restricted Target List will identify whether
the Pre-Existing Restrictions are exclusive, non-exclusive or co-exclusive. If the Target is under development at Arcturus, Arcturus
will provide the Trusted Arcturus Employee with Proof of Concept Data. Arcturus represents, warrants and covenants to CureVac that
(i) the Restricted Target List is and will at all times be accurate in accordance with this Section 4.2(a); and (ii) Arcturus
will not add any Reserved Targets to the Restricted Target List and will not engage in any research, development or other activities
with respect to a Reserved Target or grant to any Third Party any licenses or options under the Arcturus LMD Technology with respect
to the then current Reserved Target List that would preclude Arcturus from entering into a License Agreement with respect to such
Reserved Target as set forth herein.

 

    	 	2	 

     

    

 

		(b)	Target Notices.

 

From
time to time during the Term, if CureVac desires to include a Target as a Reserved Target hereunder, CureVac will notify the Trusted
Arcturus Employee in writing of the Targets for potential inclusion on the Reserved Target List, which notice will provide (i)
the information on the Target Reservation Request Form attached hereto as Exhibit 4.2; and (ii) the identity
of each Reserved Target (if any) that CureVac desires to remove as a Reserved Target (each such notice, a “Target Notice”).
For clarity, the Target Notices shall not include more Targets than the Maximum Targets then available (taking into consideration
any removed Targets previously reserved) and shall be deemed to be a request for an exclusive license at the outset unless there
is a Pre-Existing Restriction. For clarity, CureVac’s rights to enter into a Non-Exclusive License Agreement shall apply
only if the Pre-Existing Restriction permits a non-exclusive license right to such proposed Reserved Target.

 

In addition
to the formal Target reservation mechanism described in Section 4.2(b)(i), the Trusted Arcturus Employee will in good faith respond
to any interim requests (not to exceed three (3) requests per month) on whether certain Targets can be reserved as Reserved Targets,
in order to assist CureVac in planning of development projects. For clarity, the interim requests shall not include more than the
Maximum Target then available (taking into consideration any removed Targets previously reserved).

 

		(c)	Target Response Notices.

 

(i)       The
Trusted Arcturus Employee, on behalf of Arcturus, will review each Target Notice provided by CureVac hereunder to determine whether
or not any such proposed Target is on the Restricted Target List and if listed, the applicable Pre-Existing Restriction as of the
date of such Target Notice. Within ten (10) Business Days of the Trusted Arcturus Employee’s receipt of a Target Notice,
the Trusted Arcturus Employee will provide CureVac with written notice that includes the information set forth in subsection (c)(ii)
and (iii) (each such notice, a “Target Response Notice”).

 

If, as of the date of CureVac’s
Target Notice for a Target, such Target is on the Restricted Target List and is listed as being subject to Pre-Existing Restrictions,
then such Target shall not be available to become a Reserved Target. The Target Response Notice issued for such Target will certify
to CureVac that such Target is on the Restricted Target List and is listed as being subject to Pre-Existing Restrictions. The Target
Response Notice issued for such Target shall identify whether the Target is subject to Third Party rights or is under development
at Arcturus. If the Target is subject to Third Party rights, the Target Response Notice shall identify whether the Pre-Existing
Restrictions are exclusive, non-exclusive or co-exclusive. If the Target is under development at Arcturus, upon CureVac’s
request, Arcturus shall provide to CureVac Proof of Concept Data within five (5) Business Days following such request in order
to enable CureVac to confirm that the Proof of Concept Data is sufficient for Arcturus to reject the qualification of the Target
as Reserved Target.

 

If, as of the date of CureVac’s
Target Notice for a Target, such Target is not listed on the Restricted Target List, then such Target will become a Reserved Target
and will be added to the Reserved Target List subject to the Concurrent Reserved List Limits set forth in subsection (d) below.
To the extent that the Pre-Existing Restriction is non-exclusive, then such Target may be added by CureVac to the Reserved Target
List, but CureVac shall only have the right to enter into a Non-Exclusive License Agreement.

 

(iv)       In
case of a dispute between the Parties as to whether a Target is eligible to become a Reserved Target, the Parties will involve
an independent Third Party qualified scientist mutually agreed upon by both Parties (the “Auditor”) within ten
(10) Business Days as of the date of the Target Response Notice. Promptly upon the Auditor’s designation, Arcturus shall
submit to the Auditor all documents and materials which are necessary for the Auditor to identify the Pre-Existing Restrictions.
The Auditor shall determine whether the Target is eligible to become a Reserved Target in accordance with the applicable provisions
of this Agreement. The Auditor’s determination shall be binding upon the Parties. The Auditor shall be required to enter
into a reasonably acceptable confidentiality agreement and will not share any information provided by Arcturus to CureVac or any
Third Party.

 

    	 	3	 

     

    

 

(d)       Concurrent
Reserved List Limits and Removal of Targets. The following concurrent reserved list limits will apply to all Reserved
Targets (“Concurrent Reserved List Limits”).

 

(i)       Reserved
Targets and Removal thereof. CureVac may select Reserved Targets up to the totals allowed for in subparagraph (ii) below, in
accordance with the process specified in Sections 4.2(b) and (c). CureVac shall have the right to remove a Target or replace a
Target on the Reserved Target List with another Target, in accordance with the process specified in Section 4.2(b), provided (A)
the total number of Targets on the Reserved Target List does not exceed the Maximum Targets at any one time; and (B) a newly nominated
Target is not on the Restricted Target List. Any abandoned Target(s) revert(s) back to Arcturus.

 

(ii)       Maximum
Number Reserved Targets. CureVac will have the right to select up to [*****] at any one time to be placed on the Reserved
Target List as Reserved Targets; provided that the [*****] total shall be reduced by each delivery of an Acceptance Notice (the “Maximum
Targets”) (e.g., if [*****] License Agreements have been executed, then the total number of Reserved Targets shall be reduced
to [*****]), with such reduction in the total Targets applying from and after the date of exercise of an Acceptance Notice.

 

4.3       Expiration
of Pre-Existing Restrictions. If any Pre-Existing Restrictions identified in a Target Response Notice that precluded
Arcturus from granting CureVac a license (whether or not CureVac has elected to designate such Target on the Reserved Target List
on a non-exclusive basis subject to the Pre-Existing Restriction) under the Arcturus LMD Technology later expire or otherwise are
modified or terminated such that Arcturus is no longer precluded under the terms of the applicable Third Party agreement from granting
a license to CureVac with respect to such Target, the Trusted Arcturus Employee will notify CureVac of such event and CureVac will
have an exclusive option, for a period of thirty (30) days following delivery of notice to CureVac, to add (or extend its rights)
such Target to the Reserved Target List as a Reserved Target in accordance with Section 4.2(c), subject to the Concurrent Reserved
List Limits. For clarity, CureVac will at all times thereafter have the right to provide a Target Notice for such Target to the
Trusted Arcturus Employee pursuant to Section 4.2(b) but such Target Notice will be subject to any intervening Pre-Existing Restrictions.

 

4.4       Trusted
Arcturus Employee. Arcturus shall ensure that the Trusted Arcturus Employee abides by the terms set forth herein. On
the Third Amendment Date, (i) Arcturus shall communicate the name, title and contact details of the Trusted Arcturus Employee to
CureVac and (ii) Arcturus and CureVac will terminate - if - any existing Escrow Agreement and jointly instruct and permit the Escrow
Agent to send the current Reserved Target List to the Trusted Arcturus Employee. Arcturus shall ensure that only the Trusted Arcturus
Employee knows the identity of Reserved Targets and that the Trusted Arcturus Employee is bound by obligations of confidentiality
obliging the Trusted Arcturus Employee to keep the Reserved Target List and the identity of Reserved Targets confidential. All
costs and expenses incurred through the Trusted Arcturus Employee after the Third Amendment Date will be borne by Arcturus. If
Arcturus appoints a new Arcturus employee to serve as the Trusted Arcturus Employee after the Third Amendment Date, Arcturus shall
promptly notify CureVac of such appointment.

 

		4.	FURTHER AMENDMENTS

 

		(a)	Section 1.69 of the Development and Option Agreement (Definition of Pre-Existing Restrictions)
is hereby amended and restated in its entirety as follows:

 

		(b)	“1.69“Pre-Existing Restrictions” means, with respect to a Target
on the Restricted Target List pursuant to Section 4.2(a), that (i) Arcturus or its Affiliates have granted to a Third Party with
respect to such Target a non-exclusive, co-exclusive or an exclusive license or option pursuant to a bona fide written agreement
that is in effect at the date of the Target Notice by CureVac pursuant to Section 4.2, restricting Arcturus from granting the applicable
license to CureVac under the LMD Technology with respect to such Target, or (ii) such Target is under development at Arcturus and
Arcturus has completed, at minimum, preclinical in vivo Proof of Concept Data with respect to such Target.

 

		(c)	Section 1.77 of the Development and Option Agreement (Definition of Reserved Target) is hereby
amended and restated in its entirety as follows:

 

“1.77“Reserved
Target” means a Target (i) which is included in the Reserved Target List on the Third Amendment Date or (ii) with respect
to which CureVac shall have delivered to the Trusted Arcturus Employee a Target Notice and in response thereto the Trusted Arcturus
Employee shall have delivered to CureVac a Target Response Notice under Section 4.2(c)(i) for such Target to become a Reserved
Target. A Reserved Target that is abandoned or replaced pursuant to Section 4.2 will no longer be deemed a Reserved Target.”

 

    	 	4	 

     

    

 

		(d)	The following Sections are inserted immediately following Section 1.97 of the Development and Option
Agreement:

 

“1.98       “Trusted
Arcturus Employee” means an employee (not on the C-Level or business development) of Arcturus designated by Arcturus,
being the only individual in the Arcturus’ organization who knows the CureVac Reservation List, steering the Target Response
Notice.

 

1.99       “Proof
of Concept Data” means any of the following: (i) data for two mRNAs encoding a Target with positive results (i.e. a biological
and/or pharmacological effect) in at least one in vivo study (i.e. in animals); or (ii) data for two mRNAs encoding
a Target demonstrating in vivo expression of the encoded Target.

 

1.100       “Auditor”
has the meaning set forth in Section 4.2(c)(iv).

 

5.       Disclosure

 

The
Parties will mutually agree upon a Form 8-K to be filed by Arcturus with the Securities and Exchange Commission to disclose this
Third Amendment (the “Form 8-K”). Except for the Form 8-K, unless required by applicable law, neither
Party will disclose any information relating to the circumstances which have led to the amendment of the Development and Option
Agreement or the amendment of the Development and Option Agreement (including the terms of this Third Amendment).

 

7.       Non-Disparagement

 

Neither Party or any
of its Affiliates shall make any statements, verbal or written, or cause or encourage others to make any statements, verbal or
written, that defame, disparage, or in any way criticize the personal or business reputation, practices, or conduct of, the other
Party or its shareholders, directors, officers, employees, or agents, including but not limited to statements made regarding the
past relationship and past interactions between the Parties. This prohibition extends to statements, verbal or written, made to
anyone, including but not limited to, the news media, investors, potential investors, any board of directors or advisory board
of directors, industry analysts, competitors, strategic partners, vendors, employees (past and present), and clients. Any breach
of this paragraph shall be a material breach of the Development and Option Agreement. For the avoidance of any doubt, this Section
7 shall not prohibit the disclosure of any factual statements required by applicable Law.

 

8.       Representations
and Warranties

 

Each Party represents
and warrants to the other as of the Third Amendment Date that (a) it is a corporation duly organized, validly existing, and in
good standing under the Laws of the jurisdiction in which it is incorporated, (b) it has the legal right and power to enter into
this Third Amendment, to extend the rights and licenses granted or to be granted to the other in the Development and Option Agreement,
and to fully perform its obligations hereunder, (c) it has taken all necessary corporate action on its part required to authorize
the execution and delivery of this Third Amendment and the performance of its obligations under the Development and Option Agreement
(d) this Third Amendment has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding
obligation of such Party that is enforceable against it in accordance with its terms, and (e) the execution, delivery and performance
by a Party of this Third Amendment and the consummation of the transactions contemplated hereby will not result in any violation
of, conflict with, result in a breach of or constitute a default under any understanding, contract or agreement to which such Party
is a party or by which it is bound.

 

9.       Ratification
of Development and Option Agreement

 

Except as expressly
provided in this Third Amendment, all of the terms, covenants, and other provisions of the Development and Option Agreement are
hereby ratified and confirmed and shall continue to be in full force and effect in accordance with their respective terms. From
and after the date hereof, all references to the Development and Option Agreement shall refer to the Development and Option Agreement
as amended by this Third Amendment. Capitalized terms used but not defined in this Amendment shall have the meanings assigned to
them in the Development and Option Agreement.

 

    	 	5	 

     

    

 

10.       Governing
Law

 

This Third Amendment
shall be governed by and construed in accordance with the Laws of the State of New York, USA, without respect to its conflict of
Laws rules. In the event of a dispute arising out of or relating to this Third Amendment, the provisions of Section 10.1 of the
Development and Option Agreement shall govern the resolution of such dispute.

 

11.       Counterparts

 

This Third Amendment
may be executed and in one or more counterparts, each of which will be deemed an original, and all of which together will be deemed
to be one and the same instrument. Facsimile or PDF execution and delivery of this Third Amendment by either Party will constitute
a legal, valid and binding execution and delivery of this Third Amendment by such Party.

 

[signature page follows]

 

    	 	6	 

     

    

 

IN WITNESS WHEREOF,
the Parties intending to be bound have caused this Third Agreement to be executed by their duly authorized representatives as of
the Effective Date.

 

	Arcturus Therapeutics, Inc.	 	CureVac AG
	By:	/s/ Joseph Payne	 	By:	/s/ Daniel Menichella
	Name:	Joseph Payne	 	Name:	Daniel Menichella
	Title:	Chief Executive Officer	 	Title:	Chief Executive Officer
	 	 	 	By:	/s/ Dr. Franz-Werner Haas
	 	 	 	Name:	Dr. Franz-Werner Haas
	 	 	 	Title:	Chief Operating Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]